Table 1.
Ocular symptoms of 108 European non-hospitalized patients (216 eyes) with COVID-19
| Ocular symptoms | Right and left eyes with symptoms, no. (%) | Patients with bilateral symptoms, n (%) | Duration of occurrence since first symptom was noted (days), mean ± SD (range) |
|---|---|---|---|
| Burning sensations | 76 (35.2%) | 37 (34.3%) | 1.89 ± 3.26 (range 0–13) |
| Itching | 38 (17.6%) | 18 (16.7%) | 2.53 ± 3.72 (range 0–13) |
| Epiphora (watering eyes) | 71 (32.9%) | 34 (31.5%) | 1.91 ± 3.59 (range 0–13) |
| Mucoid discharge | 18 (8.3%) | 9 (8.3%) | 0.78 ± 1.09 (range 0–13) |
| Purulent discharge | 0 (0.0%) | 0 (0.0%) | — |
| Photophobia | 44 (20.4%) | 22 (20.4%) | 1.77 ± 3.41 (range 0–13) |
| Foreign body sensation | 15 (6.9%) | 7 (6.5%) | 2.25 ± 2.12 (range 0–6) |
| Conjunctival swelling | 16 (7.4%) | 8 (7.4%) | 1.14 ± 1.46 (range 0–3) |
| Eyelid swelling | 30 (13.9%) | 15 (13.9%) | 2.00 ± 2.88 (range 0–10) |
| Feeling of pressure | 45 (20.8%) | 22 (20.4%) | 2.04 ± 2.40 (range 0–7) |
| Double images | 4 (1.9%) | 2 (1.9%) | 3.50 ± 2.12 (range 2–5) |
| Metamorphopsia | 0 (0.0%) | 0 (0.0%) | — |
| Redness | 54 (25.0%) | 26 (24.1%) | 2.07 ± 2.67 (range 0–10) |
| Reduced visual acuity | 19 (8.8%) | 9 (8.3%) | 3.10 ± 2.60 (range 0–7) |
| Pain | 22 (10.2%) | 11 (10.2%) | 2.09 ± 2.12 (range 0–7) |